Cargando…

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects

INTRODUCTION: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lievense, Lysanne A., Heukels, Peter, van Walree, Nico C., van der Leest, Cor H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791802/ https://www.ncbi.nlm.nih.gov/pubmed/36578272 http://dx.doi.org/10.1016/j.jtocrr.2022.100441

Ejemplares similares

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
por: Arigami, Takaaki, et al.
Publicado: (2020)

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
por: Brouns, Anita J.W. M., et al.
Publicado: (2023)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Revisiting immune escape in colorectal cancer in the era of immunotherapy
por: Ijsselsteijn, Marieke Erica, et al.
Publicado: (2019)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
por: Chen, Yiqun, et al.
Publicado: (2023)

Activities Forgone because of Chronic Breathlessness: A Cross-Sectional Population Prevalence Study
por: Kochovska, Slavica, et al.
Publicado: (2020)

Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection
por: Israël, Bas, et al.
Publicado: (2022)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Hoodies Up, SAHM! Preventing Adversity Because of Racism for the Next Generation
por: Trent, Maria
Publicado: (2020)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Frequency of low-grade adverse events and quality of life during chemotherapy determine patients’ judgement about treatment in advanced-stage thoracic cancer
por: de Mol, Mark, et al.
Publicado: (2019)

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment
por: van Montfort, Lieke, et al.
Publicado: (2017)

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
por: Nakai, Yasutomo, et al.
Publicado: (2021)

BECAUSE Workshop
por: Collective
Publicado: (1994)

Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis
por: Gilmore, Elaine S., et al.
Publicado: (2020)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Primary and metastatic breast tumors cross-talk to influence immunotherapy responses
por: Oliver, Amanda J, et al.
Publicado: (2020)

“Because This Is an Evidence-Based Program”: The Learning Experience of Croatia with the Lions Quest Skills for Adolescence, Implemented In-Person and Online
por: El-Khatib, Ziad, et al.
Publicado: (2022)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Efficacy of Biofeedback Therapy before and after Sphincteroplasty for Fecal Incontinence because of Obstetric Injury: A Randomized Controlled Trial
por: Ghahramani, Leila, et al.
Publicado: (2016)

Multi‐organs perioperative immune‐related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC
por: Xu, Yuan, et al.
Publicado: (2022)

Brian Cox We're doing it not because it's easy, but because it's hard
Publicado: (2009)

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review
por: Liu, Jason, et al.
Publicado: (2023)

Because Others Do
por: Pratt, Ben. H.
Publicado: (1879)

Focal and generalized seizure activity after local hippocampal or cortical ablation of Na(V)1.1 channels in mice
por: Jansen, Nico A., et al.
Publicado: (2020)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
por: Hu, Yue, et al.
Publicado: (2023)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring
por: Connell, Claire M., et al.
Publicado: (2017)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
por: Zhang, Chenxing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dqhvo5l298ps3a6ugnn0vn81de